Growth Prospects of the Thalassemia-Pipeline Review, H2 2016
Thalassemia-Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Thalassemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects.
To access full report with TOC, please visit Thalassemia-Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Thalassemia
- The report reviews pipeline therapeutics for Thalassemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Thalassemia therapeutics and enlists all their major and minor projects
- The report assesses Thalassemia therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Thalassemia
- The report reviews pipeline therapeutics for Thalassemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Thalassemia therapeutics and enlists all their major and minor projects
- The report assesses Thalassemia therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Thalassemia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thalassemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thalassemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Acceleron Pharma, Inc. Acetylon Pharmaceuticals, Inc. Acino International AG Agios Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Bellicum Pharmaceuticals, Inc. Bluebird bio, Inc. Editas Medicine, Inc. Emmaus Medical, Inc. Errant Gene Therapeutics, LLC Gamida Cell Ltd. Gilead Sciences, Inc. Incyte Corporation Ionis Pharmaceuticals, Inc. IRBM Science Park SpA Johnson & Johnson Kiadis Pharma N.V. La Jolla Pharmaceutical Company Merck & Co., Inc. Pfizer Inc. PharmaEssentia Corporation Sangamo BioSciences, Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 22:44
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home